LMR Partners’s Harvard Bioscience HBIO Stock Holding History

LMR Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,401	Closed	-$36K	–	1180
2022 Q3	$36K	Hold	1,401	–	–	﹤0.01%	1125
2022 Q2	$50K	Buy	+1,401	New	+$63.2K	﹤0.01%	1162
2019 Q4	–	Sell	-4,844	Closed	-$149K	–	467
2019 Q3	$149K	Hold	4,844	–	–	0.01%	352
2019 Q2	$97K	Buy	+4,844	New	+$142K	﹤0.01%	366
2016 Q3	–	Sell	-2,720	Closed	-$78K	–	397
2016 Q2	$78K	Buy	+2,720	New	+$86.5K	0.01%	415
2014 Q4	–	Sell	-3,543	Closed	-$144K	–	410
2014 Q3	$144K	Sell	3,543 -2,268	-39%	-$104K	0.01%	269
2014 Q2	$265K	Buy	+5,811	New	+$244K	0.02%	356

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

LMR Partners's HBIO Position: Q4 2022 in Review

LMR Partners sold out of Harvard Bioscience (HBIO) in Q4 2022, closing a stake of 1,401 shares — an estimated $36K sold.

LMR Partners first reported a position in HBIO in Q2 2014 and held it in 7 quarters. The position peaked at $265K in Q2 2014. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2022.

LMR Partners reported no remaining Harvard Bioscience position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 1,401 Harvard Bioscience shares in Q4 2022, an estimated $36K.
LMR Partners first reported a position in Harvard Bioscience in Q2 2014 and held it in 7 quarters.
LMR Partners's Harvard Bioscience position peaked at $265K in Q2 2014.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.